SCHEMBL3523802

SCHEMBL3523802

COC(=O)CCCC#Cc1cc(Cl)ccc1NS(=O)(=O)c1ccc2c(c1)OCO2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.47
GLA P06280 1/20 0.47
ALDH1A1 P00352 3/20 0.44
TSHR P16473 4/20 0.44
KDM4E B2RXH2 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MAPT P10636 5/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MAPK1 P28482 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3522927 0.95 KDM4E (0.50) LMNAALDH1A1TSHRKDM4ESMN1; SMN2
SCHEMBL3526458 0.95 LMNA (0.48) LMNAGLAALDH1A1TSHRKDM4E
SCHEMBL3522237 0.87 PKM (0.49) LMNAALDH1A1TSHRKDM4ESMN1; SMN2
SCHEMBL3529176 0.87 MAPT (0.43) LMNAGLAALDH1A1TSHRKDM4E
SCHEMBL3528604 0.84 PTGES2 (0.47) ALDH1A1HPGDHDAC3HDAC4HDAC1
SCHEMBL3525068 0.83 LMNA (0.51) LMNAALDH1A1TSHRMAPTHPGD
SCHEMBL3528825 0.83 ALDH1A1 (0.56) ALDH1A1CCR2CCR9
SCHEMBL3525207 0.83 PKM (0.45) LMNAALDH1A1HPGDCCR2CCR9
SCHEMBL3527145 0.83 CCR2 (0.45) LMNAALDH1A1MAPTNPSR1MAPK1
SCHEMBL3523112 0.82 CCR9 (0.42) LMNAMAPTCCR2CCR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP LMNA 849/4885GLA 651/4885ALDH1A1 1607/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG LMNA 1980/4885GLA 1129/4885ALDH1A1 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.